Connection

George Magrath to Integrins

This is a "connection" page, showing publications George Magrath has written about Integrins.
Connection Strength

0.203
  1. The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study. Ophthalmic Surg Lasers Imaging Retina. 2022 10; 53(10):553-560.
    View in: PubMed
    Score: 0.203
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.